Reduction of elevated arterial blood pressure in obese Zucker rats by inhibition of ganglionic long-term potentiation.
Sustained enhancement of the basal tone of ganglionic transmission is expected to result in an enduring increase in peripheral resistance that would lead to elevated blood pressure. Long-term potentiation of sympathetic ganglia is an activity-dependent long-lasting increase in strength of ganglionic transmission. Therefore, ganglionic long-term potentiation might be involved in the manifestation of neurogenic forms of hypertension. Expression of sympathetic ganglionic long-term potentiation is dependent on activation of 5-HT(3) receptor. We examined the possibility that elevated blood pressure in obese Zucker rat, which is reported to be stress-prone, might be partly due to a neurogenic factor resulting from expression of ganglionic long-term potentiation. Chronic treatment with the 5-HT(3) receptor antagonist ondansetron (0.5 mg/kg/day) caused a significant decrease in blood pressure of the obese Zucker rats without affecting that of normotensive lean Zucker rats. Electropysiological procedures to test for long-term potentiation in isolated ganglia suggest that ganglionic long-term potentiation has been previously expressed in vivo in ganglia from obese Zucker rat but not in those from the normotensive lean Zucker rats. The results indicate that expression of ganglionic long-term potentiation in sympathetic ganglia may be responsible for neurogenic increase in blood pressure, which contributes to the moderate hypertension often seen in the obese Zucker rats.
Gerges
N Z
NZ
Department of Pharmacological and Pharmaceutical Sciences, University of Houston, TX, Houston 77204-5515, USA.
Aleisa
A M
AM
Alhaider
A A
AA
Alkadhi
K A
KA
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D005724:Ganglia / Q000187:drug effects / Q000502:physiology*; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D066298:In Vitro Techniques; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D017294:Ondansetron / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D011924:Rats, Zucker; D011985:Receptors, Serotonin / Q000502:physiology; D044406:Receptors, Serotonin, 5-HT3
D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D017294:Ondansetron